Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 16;13(1):e12221. doi: 10.1002/clt2.12221

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Dupilumab measured in conjunctival cells obtained by conjunctival impression cytology. (A) Dupilumab measured in conjunctival cell suspensions from 5 dupilumab‐treated AD patients (at week 4) and 3 AD control patients (not treated with dupilumab) by using LC‐MS/MS. (B) Median Fluorescence Intensity (MFI) of IgG4 (= anti‐dupilumab) in CD45‐epithelial cells from 4 dupilumab‐treated AD patients (at week 4) compared to the control staining including only the secondary antibody (AB) streptavidine‐APC. (C) MFI of IL‐4Rα on CD45‐cells from 4 AD patients before dupilumab treatment (baseline) and after 4 weeks of treatment.